Loading...
Keywords
Last Name
Institution

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Adolescents =5 to <18 Years of Age


Collapse Biography 
Collapse contributor

Collapse Overview 
Collapse sponsor award id
C4591007

Collapse Time 
Collapse start date
2021-04-01
Collapse end date
2024-03-31